Related Experiment Video
Updated: Jun 24, 2026
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
[Blood transfusion therapy for massive hemorrhage associated with scheduled peritonectomy for pseudomyxoma peritonei
Makoto Satani1, Noriaki Oomae, Asami Tomita
1Department of Anesthesia, Kishiwada Tokushukai Hospital, Kishiwada 596-0042.
Background:
The component therapy has been recommended for surgical hemorrhage. We investigated whether the component therapy was useful for surgical patients undergoing the scheduled peritonectomy for pseudomyxoma peritonei or peritoneal dissemination.
Methods:
Twenty patients were divided into two groups (the component therapy for 7 patients and the early transfusion of flesh frozen plasma therapy for 13 patients). We studied the change of prothrombin time (PT), hepaplastin test (HPT) and fibrinogen level during operations.
Results:
In the component therapy group, PT, HPT and fibrinogen level decreased to 28.5 +/- 11.8%, 25.9 +/- 9.3%, 99.5 +/- 61.3 mg x dl(-1), respectively, during surgical intervention, but no difference was found postoperatively between the two groups. One patient in the component therapy group was reoperated for bleeding.
Conclusions:
If the hemorrhage of more than the circulation volume is suspected before the operation, early transfusion therapy seems to provide good effect for coagulation in scheduled peritonectomy of pseudomyxoma peritonei or peritoneal dissemination.
